In Stage 4 MYCN amplified neuroblastoma patients, TRPM2 expression did not correlate significantly with outcome, possibly because MYCN itself transcriptionally regulates expression of many oncogenic proteins including FOXM143. This evidence concerns the gene TRPM2 and neuroblastoma.